|
Thyroid Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
LARP7 acts as a tumor suppressor in breast and gastric cancer, and possibly, according to recent studies, in thyroid tumors.
|
31656314 |
2020 |
|
Familial Nonmedullary Thyroid Cancer
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Whole exome sequencing revealed two novel LARP7 variants in compound heterozygosity, whereas only common variants were detected in genes associated with familial nonmedullary thyroid cancer (MIM#188550).
|
31656314 |
2020 |
|
Seckel syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here we describe two consanguineous Algerian sisters with Alazami PD due to LARP7 homozygous pathogenic variants detected by whole exome sequencing.
|
30006060 |
2019 |
|
Papillary thyroid carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression levels of LARP7 were significantly downregulated in PTC tissues and cell lines.
|
29620212 |
2018 |
|
Trichohepatoenteric Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This study is an independent confirmation of the syndrome due to LARP7 depletion.
|
26607181 |
2016 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
As emerging research uncovers the function of each LARP, it is evident that La, LARP1, LARP6, LARP7 and possibly LARP4a and 4b are dysregulated in cancer.
|
26501340 |
2015 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
As emerging research uncovers the function of each LARP, it is evident that La, LARP1, LARP6, LARP7 and possibly LARP4a and 4b are dysregulated in cancer.
|
26501340 |
2015 |
|
Malignant neoplasm of breast
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Decreased levels of LARP7 and 7SK snRNA redistribute P-TEFb to the transcriptionally active super elongation complex, resulting in P-TEFb activation and increased transcription of EMT transcription factors, including Slug, FOXC2, ZEB2, and Twist1, to promote breast cancer EMT, invasion, and metastasis.
|
25053741 |
2014 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Decreased levels of LARP7 and 7SK snRNA redistribute P-TEFb to the transcriptionally active super elongation complex, resulting in P-TEFb activation and increased transcription of EMT transcription factors, including Slug, FOXC2, ZEB2, and Twist1, to promote breast cancer EMT, invasion, and metastasis.
|
25053741 |
2014 |
|
Breast Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Decreased levels of LARP7 and 7SK snRNA redistribute P-TEFb to the transcriptionally active super elongation complex, resulting in P-TEFb activation and increased transcription of EMT transcription factors, including Slug, FOXC2, ZEB2, and Twist1, to promote breast cancer EMT, invasion, and metastasis.
|
25053741 |
2014 |
|
Malignant transformation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Consistent with the tumor suppressor role of a Drosophila homolog of PIP7S, loss of PIP7S function shifts the P-TEFb equilibrium toward the active state, disrupts epithelial differentiation, and causes P-TEFb-dependent malignant transformation.
|
18249148 |
2008 |
|
Malignant neoplasm of stomach
|
0.020 |
Biomarker
|
disease |
BEFREE |
LARP7 acts as a tumor suppressor in breast and gastric cancer, and possibly, according to recent studies, in thyroid tumors.
|
31656314 |
2020 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
LARP7 acts as a tumor suppressor in breast and gastric cancer, and possibly, according to recent studies, in thyroid tumors.
|
31656314 |
2020 |
|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
LARP7 mRNA was significantly decreased in GCs (median 2.5) relative to N(N)s (median 14.9, P<0.01) as well as relative to their corresponding N(GC)s (median 8.1, P<0.01).
|
22488152 |
2012 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Taken together, these findings suggest that LARP7 downregulation occurs early during gastric tumorigenesis and may promote gastric tumorigenesis via p-TEFb dysregulation.
|
22488152 |
2012 |
|
Stomach Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
LARP7 is a potential tumor suppressor gene in gastric cancer.
|
22488152 |
2012 |
|
Carcinogenesis
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Through PIP7S modulation of P-TEFb, our data thus link a general elongation factor to growth control and tumorigenesis.
|
18249148 |
2008 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
LARP7 acts as a tumor suppressor in breast and gastric cancer, and possibly, according to recent studies, in thyroid tumors.
|
31656314 |
2020 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Overexpression of LARP7 inhibited the proliferation and increased the radioiodine uptake ability of PTC cells in vitro and inhibited the tumor growth in vivo.
|
29620212 |
2018 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
LARP7 is a potential tumor suppressor gene in gastric cancer.
|
22488152 |
2012 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Consistent with the tumor suppressor role of a Drosophila homolog of PIP7S, loss of PIP7S function shifts the P-TEFb equilibrium toward the active state, disrupts epithelial differentiation, and causes P-TEFb-dependent malignant transformation.
|
18249148 |
2008 |
|
Interleukin 16 Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genome-wide Association Study Identifies 27 Loci Influencing Concentrations of Circulating Cytokines and Growth Factors.
|
27989323 |
2017 |
|
Anxiety
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Atrial Septal Defects
|
0.100 |
Biomarker
|
group |
HPO |
|
|
|
|
Macrostomia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|